Acepodia, Inc. (TPEX:6976)

Taiwan · Delayed Price · Currency is TWD

11.85

+0.05 (0.42%)

Aug 18, 2026, 1:41 PM CST

-22.55% (1Y)

Market Cap	6.91B -22.4%
Revenue (ttm)	n/a -31.9%
Net Income	-828.06M
EPS	-1.42
Shares Out	582.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,265
Open	11.85
Previous Close	11.80
Day's Range	11.85 - 11.85
52-Week Range	10.85 - 19.15
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands. [Read more]

Industry Biotechnology

Sector Healthcare

CEO Shih-Chia Hsiao

Country Cayman Islands

Stock Exchange Taipei Exchange

Ticker Symbol 6976

Full Company Profile

Financial Performance

In 2025, Acepodia's revenue was 185,000, a decrease of -56.67% compared to the previous year's 427,000. Losses were -754.40 million, 51.9% more than in 2024.

Financial Statements